Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: The role of human equilibrative nucleoside transporter 1

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3171-3180

  Wang, Honggang ^a   Word, Beverly R ^a   Lyn Cook, Beverly D ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Cytotoxicity; Gemcitabine; hENT1; I3C; Pancreatic cancer

Indexed keywords

3 INDOLEMETHANOL; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; MONOTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

CELL DEATH; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG SYNERGISM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; PANCREATIC NEOPLASMS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 80054749399     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Abbruzzese JL: New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 95: 941-945, 2002.
2. Jemal A, Center MM and Ward E: The convergence of lung cancer rates between blacks and whites under the age of 40, United States. Cancer Epidemiol Biomarkers Prev 18: 3349-3352, 2009.
3. Galmarini CM, Mackey JR and Dumontet C: Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15: 875-890, 2001. (Pubitemid 32529886)
4. Krishnan P, Fu Q, Lam W, Liou JY, Dutschman G and Cheng YC: Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J Biol Chem 277: 5453-5459, 2002. (Pubitemid 34968594)
5. Liou JY, Dutschman GE, Lam W, Jiang Z and Cheng YC: Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. Cancer Res 62: 1624-1631, 2002. (Pubitemid 34408481)
6. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese, J. L and Blanke CD: Phase HI study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28: 3605-3610, 2010.
7. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL and Goldberg RM: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622, 2010.7
8. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M and Buckels JA: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87: 161-167, 2002.
9. Kang SP and Saif MW: Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP 9: 83-90, 2008. (Pubitemid 351611723)
10. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M and Danesi R: Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 5: 1387-1395, 2006. (Pubitemid 44070474)
11. Takagaki K, Katsuma S, Kaminishi Y, Horio T, Nakagawa S, Tanaka T, Ohgi T and Yano J: Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells. J Biochem 136: 733-740, 2004. (Pubitemid 40364197)
12. Mackey JR, Mani RS, Seiner M, Mowles D, Young JD, Belt JA, Crawford CR and Cass CE: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58: 4349-4357, 1998. (Pubitemid 28450036)
13. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T and Ueda R: Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 95: 753-757, 2004. (Pubitemid 39335096)
14. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R and Mackey JR: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10: 6956-6961, 2004. (Pubitemid 39383046)
15. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T and Tanaka M: Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 12: 807-817, 2010.
16. Okazaki T, Javle M, Tanaka M, Abbruzzese JL and Li D: Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 16: 320-329, 2010.
17. Mori R, Ishikawa T, Ichikawa Y, Taniguchi K, Matsuyama R, Ueda M, Fujii Y, Endo I, Togo S, Danenberg PV and Shimada H: Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep 17: 1201-1205, 2007.
18. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421, 2006.
19. Arora A and Shukla Y: Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol. Cancer Lett 189: 167-173, 2003. (Pubitemid 35461993)
20. Banerjee S, Wang Z, Kong D and Sarkar FH: 3,3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 69: 5592-5600, 2009.
21. Weng JR, Omar HA, Kulp SK and Chen CS: Pharmacological exploitation of indole-3-carbinol to develop potent antitumor agents. Mini Rev Med Chem 10: 398-404, 2010.
22. Reed GA, Arneson DW, Putnam WC, Smith HJ, Gray JC, Sullivan DK, Mayo MS, Crowell JA and Hurwitz A: Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3′- diindolylmethane. Cancer Epidemiol Biomarkers Prev 15: 2477-2481, 2006. (Pubitemid 46048308)
23. Lian JP, Word B, Taylor S, Hammons GJ and Lyn-Cook BD: Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. Anticancer Res 24: 133-137, 2004. (Pubitemid 38279698)
24. Lyn-Cook BD, Mohammed SI, Davis C, Word B, Haefele A, Wang H and Hammons G: Gender differences in gemcitabine (Gemzar) efficacy in cancer cells: effect of indole-3-carbinol. Anticancer Res 30: 4907-4913, 2010.
25. Rahimi M, Huang KL and Tang CK: 3,3′-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants. Cancer Lett 295: 59-68, 2010.
26. Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S and Sarkar FH: Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 66: 10064-10072, 2006. (Pubitemid 44672060)
27. Weng JR, Tsai CH, Kulp SK and Chen CS: Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett 262: 153-163, 2008.
28. Ali S, Banerjee S, Schaffert JM, El-Rayes BF, Philip PA and Sarkar FH: Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. J Cell Biochem 110: 171-181, 2010.
29. Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M and Tanabe KK: Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 68: 2391-2399, 2008. (Pubitemid 351521814)
30. Sabbah M, Emami S, Redeuilh G, Julien S, Prevost G, Zimber A, Ouelaa R, Bracke M, De Wever O and Gespach C: Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 11: 123-151, 2008.
31. Li Y, VandenBoom TG, 2nd, Kong D, Wang Z, Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-6712, 2009.
32. Howells LM, Moiseeva EP, Neal CP, Foreman BE, Andreadi CK, Sun YY, Hudson EA and Manson MM: Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol Sin 28: 1274-1304, 2007. (Pubitemid 47366687)
33. Manach C, Williamson G, Morand C, Scalbert A and Remesy C: Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81: 230S-242S, 2005.
34. Lev-Ari S, Vexler A, Starr A, Ashkenazy-Voghera M, Greif J, Aderka D and Ben-Yosef R: Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 25: 411-418, 2007. (Pubitemid 47450667)
35. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T and Kohgo Y: Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 96: 457-463, 2007. (Pubitemid 46215217)
36. Bergmann F, Breinig M, Hopfner M, Rieker RJ, Fischer L, Kohler C, Esposito I, Kleeff J, Herpel E, Ehemann V, Friess H, Schirmacher P and Kern MA: Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol 104: 171-181, 2009.
37. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH and Abreu MT: Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133: 1869-1881, 2007.
38. Ali S, El-Rayes BF, Sarkar FH and Philip PA: Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 4: 1943-1951, 2005. (Pubitemid 43056977)
39. Fernandez Calotti P, Galmarini CM, Canones C, Gamberale R, Saenz D, Avalos JS, Chianelli M, Rosenstein R and Giordano M: Modulation of the human equilibrative nucleoside transporterl (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia. Biochem Pharmacol 75: 857-865, 2008.
40. Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC and Moore JS: Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood 89: 941-947, 1997. (Pubitemid 27121287)
41. Reeves R, Edberg DD and Li Y: Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 21: 575-594, 2001. (Pubitemid 32037376)
42. Rabbani SA and Xing RH: Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int J Oncol 12: 911-920, 1998. (Pubitemid 28133587)
43. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB and Von Hoff DD: Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 62: 2890-2896, 2002. (Pubitemid 34525776)
44. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR and Sen S: Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20: 189-193, 1998. (Pubitemid 28455454)
45. Griffiths M, Beaumont N, Yao SY, Sundaram M, Boumah CE, Davies A, Kwong FY, Coe I, Cass CE, Young JD and Baldwin SA: Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 3: 89-93, 1997. (Pubitemid 27019148)
46. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A and Pastor-Anglada M: Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res 9: 5000-5008, 2003. (Pubitemid 37323307)
47. Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE and Young JD: Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91: 1876-1881, 1999.
48. Hagmann W, Jesnowski R and Lohr JM: Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 12: 740-747, 2010.
49. Masumori N, Kunishima Y, Hirobe M, Takeuchi M, Takayanagi A, Tsukamoto T and Itoh T: Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. Jpn J Clin Oncol 38: 182-185, 2008. (Pubitemid 351419741)
50. Nakata B, Amano R, Nakao S, Tamura T, Shinto O, Hirakawa T, Okita Y, Yamada N and Hirakawa K: Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer. J Exp Clin Cancer Res 29: 15, 2010.